Novartis CEO Jimenez sees U.S. pricing power draining away

Carly Helfand Remember the days when drugmakers could raise prices without sparking political pushback? Novartis CEO Joe Jimenez does–and he says they're not coming back. FiercePharma ...

Shkreli’s 5th Amendment hall pass rejected for congressional drug pricing hearing

Emily Wasserman Pharma bro Martin Shkreli is requesting a hall pass to get out of testifying at a congressional hearing on drug pricing next week after receiving a subpoena ordering ...

GSK’s new $32,500 asthma med costs at least 2X too much, U.S. pricing watchdog says

Carly Helfand GlaxoSmithKline has a new drug that's tailored for patients with a specific type of severe asthma. But according to a nonprofit body that evaluates drugs' prices ...

Doctors target Catalyst Pharma’s forthcoming pricing on old-turned-new med Firdapse

Tracy Staton A new group of activist doctors has joined the drug pricing protests. This time, it's neuromuscular specialists, and they're targeting a forthcoming drug, Firdapse, ...

Pricing pressure: Doubling down on the political drama

John Carroll ​With all the brouhaha over Martin Shkreli's 5000%-plus price hike, it's important to remember what got us to this point on drug pricing and where we're left ...

Brace yourselves: The drug pricing brouhaha isn’t dying down

Tracy Staton Drug prices were already a sore subject, but the pain grew this fall, when the now-former CEO of Turing Pharmaceuticals Martin Shkreli unapologetically jacked up the price ...

Sorry, pharma. Martin Shkreli’s disgrace won’t take the heat off your pricing

Tracy Staton Pharma might think that bad boy Martin Shkreli's arrest will give the rest of the industry a breather. Though Turing Pharmaceuticals' now-ex-CEO triggered a public ...

Valeant posts 36% growth amid pricing scrutiny; may sell neurology biz

Carly Helfand Valeant may be the subject of current government scrutiny, and it may have recently suffered a stock-price freefall. But the company gave investors some good news ...

Novartis CEO: Payers not sold on performance pricing yet, but that’ll change

Tracy Staton Novartis CEO Joe Jimenez sees a couple of rays of hope for drug spending–and for the viability of higher-priced meds. Big Data, for one. And performance-based pricing ...

Novo Nordisk quells diabetes pricing fears with 2015 growth forecast

Tracy Staton Novo Nordisk has made diabetes-minded investors very happy today. Rather than following Sanofi's discouraging announcement of flat sales expectations in the field next ...

Diabetes pricing war? Sanofi, Lilly and Novo each have their ideas

Tracy Staton When Sanofi announced that its franchise would suffer next year because of U.S. payer contracts, the natural follow-up question was this: Does this mean a diabetes pricing ...

Don’t worry about a hep C pricing war, analysts tell Gilead-watchers

Tracy Staton No price war on hepatitis C drugs? That would be a disappointment to payers worried about the cost of treating millions of patients with super-expensive, yet highly effective ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS